Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin

Table 2

TLRs phenotype in CD4 and CD8 lymphocytes subpopulation.

PBMC

Sigma

Transverse

CD4 TLR2

CD8 TLR2

CD4 TLR4

CD8 TLR4

CD4 TLR2

CD8 TLR2

CD4 TLR4

CD8 TLR4

CD4 TLR2

CD8 TLR2

CD4 TLR4

CD8 TLR4

CTR

0.069±0.016

0.094±0.018

0.354±0.206

0.090±0.020

0.222±0.048

0.250±0.078

0.400±0.11

0.356±0.096

0.224±0.03

0.255±0.06

0.421±0.10

0.45±0.11

PZ

0.193±0.041^∗∗

0.244±0.037^∗

0.169±0.035^∗

0.26±0.059

0.191±0.038

0.239±0.069

0.371±0.104

0.284±0.078

0.171±0.046

0.246±0.10

0.308±0.19

0.489±0.28

BR

0.082±0.015

0.276±0.070

0.133±0.042

0.233±0.086

0.182±0.055

0.258±0.096

0.392±0.17

0.285±0.11

0.171±0.05

0.246±0.10

0.308±0.19

0.489±0.28

AR

0.115±0.044

0.161±0.045

0.197±0.084

0.221±0.074

0.092±0.029

0.143±0.057

0.076±0.037^∗

0.194±0.07

0.13±0.06

0.232±0.16

0.354±0.21

0.488±0.29

BP

0.251±0.060

0.264±0.058

0.205±0.057

0.293±0.082

0.371±0.18

0.219±0.101

0.592±0.27

0.284±0.12

ND

ND

ND

ND

AP

0.352±0.084^∗∗

0.416±0.081^∗∗

0.269±0.066

0.293±0.086

0.536±0.21

0.419±0.133^∗

1.482±0.70^∗

1.442±0.60

ND

ND

ND

ND

The values are reported as Mean ± SEM 𝑃<0.001, ^∗∗𝑃<0.01, ^∗𝑃<0.05 patients versus control (health or baseline); 𝑃<0.01, 𝑃<0.05 between treatments. Healthy control (CTR), UDD patients (PZ), before Rifaximin (BF), after Rifaximin (AR), before placebo (BP), and after placebo (AP).